Lifeloc Reports Third Quarter 2026 Results
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lifeloc Technologies (LCTC) reported third-quarter revenue of $2.522 million, with a narrower net loss than in the prior-year quarter.
Revenue grew 12% year over year. Net loss narrowed to $84,931, or $0.03 per diluted share, from $263,439, or $0.10. Gross margin rose to 43% from 40%. For the nine months ended September 30, 2026, revenue reached $7,260,643 versus $6,753,858, while net loss narrowed to $371,974 from $949,764. Operating activities generated $14,618, versus using $578,437 a year earlier.
Lifeloc now expects a limited SpinDetect launch in Q4 2027, rather than Q1 2027, while redirecting some development resources toward core alcohol-testing upgrades. Commercialization depends on incremental core-product revenue and timely access to capital. The SpinDetect disk design is complete, with oral-fluid beta testing planned under a signed agreement.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter revenue grew 12% year over year to $2,521,874.
- Moderate pointThird-quarter net loss narrowed to $84,931, or $0.03 diluted, from $263,439, or $0.10 diluted, in 2025.
- Moderate pointThird-quarter gross margin increased to 43% from 40% a year earlier.
- Moderate pointNine-month operating cash flow turned positive at $14,618, versus $578,437 used in 2025.
- Minor pointNine-month revenue increased to $7,260,643 from $6,753,858 in 2025.
14 minor points
- Minor pointNine-month net loss narrowed to $371,974, or $0.14 diluted, from $949,764, or $0.35 diluted, in 2025.
- Minor pointNine-month gross margin increased to 44% from 41%, helped by price increases and favorable product mix.
- Minor pointThird-quarter operating loss narrowed to $50,071 from $234,326 a year earlier.
- Minor pointNine-month operating loss narrowed to $281,649 from $893,139 a year earlier.
- Minor pointThird-quarter sales and marketing expense fell to $314,948 from $341,567 a year earlier.
- Minor pointThird-quarter general and administrative expense fell to $319,223 from $340,705 a year earlier.
- Minor pointNine-month research, development and sustaining engineering expense fell to $1,480,708 from $1,551,689 in 2025.
- Minor pointNine-month sales and marketing expense fell to $949,145 from $1,015,651 in 2025.
- Minor pointNine-month general and administrative expense fell to $1,021,478 from $1,065,657 in 2025.
- Minor pointCash increased to $930,539 at September 30, 2026, from $746,001 at December 31, 2025.
- Minor pointSpinDetect microfluidic disk design is complete, with analytical chemistry occurring on the disk after sample introduction.
- Minor point. Forward-looking: it has not happened yet and may not happen.SpinDetect oral-fluid beta testing is planned under a signed beta-testing agreement, initially focused on delta-9-THC.
- Minor point. Forward-looking: it has not happened yet and may not happen.Core alcohol-testing upgrades are prioritized; Lifeloc expects incremental revenue to help fund SpinDetect development.
- Minor point. Forward-looking: it has not happened yet and may not happen.SpinDetect expansion plans include additional drug panels and blood and breath samples after the limited launch.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.SpinDetect's expected limited commercial launch moved to Q4 2027 from Q1 2027.
- Moderate point. Forward-looking: it has not happened yet and may not happen.SpinDetect commercialization depends on incremental core-product revenue and timely access to capital.
- Moderate pointRelated-party term debt at September 30, 2026 included $59,396 current and $440,604 noncurrent, versus none at year-end 2025.
- Minor pointThird-quarter research, development and sustaining engineering expense increased to $505,982 from $458,747 a year earlier.
- Minor pointThird-quarter interest expense rose to $43,594 from $36,953 a year earlier.
6 minor points
- Minor pointNine-month interest expense rose to $114,446 from $87,753 in 2025.
- Minor pointRoyalty revenue fell to $9,344 for Q3 and $23,657 for nine months, versus $16,117 and $41,588 in 2025.
- Minor pointNine-month rental income fell to zero from $16,632 in 2025.
- Minor pointNine-month interest income declined to $24,121 from $31,128 in 2025.
- Minor pointStockholders' equity declined to $3,731,804 at September 30, 2026, from $4,103,778 at December 31, 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential SpinDetect applications beyond drug testing require additional research, regulatory clearances and potential license-rights expansion.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WHEAT RIDGE, CO / ACCESS Newswire / November 16, 2026 / Lifeloc Technologies, Inc. (OTCID:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended September 30, 2026.
Third Quarter Financial Highlights
Lifeloc posted quarterly net revenue of
Alcohol Detection Products
We believe our core alcohol detection product lineup is strong. The L-series LX9 and LT7 units have features and performance that drive market penetration by addressing previously unmet market needs such as smartphone pairing, wider temperature use ranges and fast customization that incorporates local languages. We expect that sales of our newer L-series devices will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as the latest AS 3547:2019 standards for Breath Alcohol Detectors from SAI Global (formerly Standards Australia International). Our FC-series devices remain popular with many law enforcement and international organizations. Our Easycal® automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around our brand and has contributed to market share gains across the board, especially for our workplace Phoenix® 6.0 BT and EV 30 devices.
SpinDetect™ Analyzer Platform
We believe our most significant long-term opportunity lies at the intersection of the global need for rapid, quantitative drug detection and our proven expertise in portable testing instrumentation. Our SpinDetect™ Centrifugal Drug Analyzer - sometimes referred to as "Lab on a Disk" - is designed to address this need, enabling rapid, on-site, quantitative drug testing for use at roadside, in emergency rooms, forensic labs, and workplace testing sites. We have demonstrated the platform's ability to effectively detect delta-9-THC, cocaine, fentanyl, amphetamine/methamphetamine, morphine, MDMA, and benzodiazepines from oral fluid. We have validated our test results against liquid chromatography-mass spectrometry (LC-MS) - the definitive laboratory standard - using real-world human saliva samples, confirming a limit of detection of approximately 10 ng/ml.
We have completed the design of the SpinDetect™ microfluidic disk, with all analytical chemistry now occurring on the disk after sample introduction. We will be initiating beta testing of the oral-fluid analyzer focused on delta-9-THC detection using a prototype reader, with final component optimization underway, under a signed beta-testing agreement. The full commercial product is expected to measure delta-9-THC, followed by a multi-drug panel release. We previously anticipated a limited commercial launch of SpinDetect in Q1 of 2027; we now expect the limited commercial launch to occur in Q4 of 2027. In recent periods we devoted a substantial portion of our engineering and development resources to SpinDetect and, as a result, deferred upgrades and enhancements to our core breath alcohol testing products. We are redirecting a portion of those resources to our core products in the near term and will be conducting beta testing and the validation of SpinDetect with our current staff rather than with additional personnel. The upgrades to our core products will allow us to enter additional markets and generate incremental revenue, which we expect will help fund the work required to complete and bring SpinDetect to market.
Following the limited commercial launch, we plan to expand into additional drug panels and sample types, including blood and breath - the latter integrated with our LX9 breathalyzer. The SpinDetect™ reader is designed to accept multiple disk formats, which may also enable future applications beyond drug testing, such as detection of food-safety markers and environmental contaminants; these applications would require additional research, regulatory clearances, and potential expansion of our existing license rights. Our revised timeline and continued progress toward commercialization depend on our ability to generate the anticipated incremental revenue from our core products and on timely access to capital to support fabrication, validation, regulatory preparation, and market introduction. There can be no assurance that the launch will occur when currently expected.
"We are raising the priority of our alcohol testing research and development projects that can have a quick, positive impact on cash flow. While we had deferred some core business opportunities, transformational AI tools have reduced the cost and timeline for hardware and firmware upgrades, raising the return on investment for these projects," commented Dr. Wayne Willkomm, President and CEO. "Using advances in our core products to fund the big growth opportunity of the SpinDetect™ Centrifugal Drug Analyzer is consistent with our desire to fund from operations as best as we can."
About Lifeloc Technologies
Lifeloc Technologies, Inc. (OTCID:LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our website, www.lifeloc.com/investor.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, market liquidity for our shares, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our SEC filings.
Phoenix® and Easycal® are registered trademarks of Lifeloc Technologies, Inc.
SpinDetect™ is a trademark of Lifeloc Technologies, Inc.
LIFELOC TECHNOLOGIES, INC. | |||||||
ASSETS | |||||||
CURRENT ASSETS: | September 30, 2026 (Unaudited) | December 31, 2025 | |||||
Cash and cash equivalents | $ | 930,539 | $ | 746,001 | |||
Accounts receivable, net | 785,442 | 772,380 | |||||
Inventories, net | 2,678,034 | 2,633,614 | |||||
Federal and state income taxes receivable | 55,381 | 55,981 | |||||
Prepaid expenses and other | 96,747 | 60,825 | |||||
Total current assets | 4,546,143 | 4,268,801 | |||||
PROPERTY, PLANT AND EQUIPMENT: | |||||||
Land | 317,932 | 317,932 | |||||
Building | 1,928,795 | 1,928,795 | |||||
Real-time Alcohol Detection And Recognition equipment and software | 569,448 | 569,448 | |||||
Production equipment, software and space modifications | 1,366,539 | 1,366,539 | |||||
Office equipment, software and space modifications | 197,686 | 197,686 | |||||
Sales and marketing equipment and space modifications | 230,543 | 225,173 | |||||
Research and development equipment, software and space modifications | 1,444,531 | 1,213,195 | |||||
Research and development equipment, software and space modifications not in service | - | 19,595 | |||||
Less accumulated depreciation | (3,745,873 | ) | (3,538,455 | ) | |||
Total property and equipment, net | 2,309,601 | 2,299,908 | |||||
OTHER ASSETS: | |||||||
Patents, net | 65,324 | 71,039 | |||||
Deposits and other | 81,560 | 46,820 | |||||
Total other assets | 146,884 | 117,859 | |||||
Total assets | $ | 7,002,628 | $ | 6,686,568 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
CURRENT LIABILITIES: | ||||||||
Accounts payable | $ | 543,342 | $ | 301,627 | ||||
Term loans payable, current portion | 56,123 | 54,850 | ||||||
Term loans payable (related party), current portion | 59,396 | - | ||||||
Subordinated debentures payable, current portion | 36,897 | 33,371 | ||||||
Customer and tenant deposits | 2,689 | 25,694 | ||||||
Accrued expenses | 344,565 | 321,112 | ||||||
Deferred revenue, current portion | 60,959 | 53,716 | ||||||
Product warranty reserve | 46,500 | 46,500 | ||||||
Total current liabilities | 1,150,471 | 836,870 | ||||||
TERM LOANS PAYABLE, net of current portion and | ||||||||
debt issuance costs | 1,016,171 | 1,058,426 | ||||||
TERM LOAN PAYABLE (Related Party), net current portion and | ||||||||
debt issuance costs | 440,604 | - | ||||||
SUBORDINATED DEBENTURES PAYABLE, net of current | ||||||||
portion and debt issuance costs | 653,219 | 681,343 | ||||||
DEFERRED REVENUE, net of current portion | 10,359 | 6,151 | ||||||
Total liabilities | 3,270,824 | 2,582,790 | ||||||
COMMITMENTS AND CONTINGENCIES (Note 6) | ||||||||
STOCKHOLDERS' EQUITY: | ||||||||
Common stock, no par value; 50,000,000 shares authorized, 2,752,616 | ||||||||
shares outstanding | 5,934,314 | 5,934,314 | ||||||
Retained earnings | (2,202,510 | ) | (1,830,536 | ) | ||||
Total stockholders' equity | 3,731,804 | 4,103,778 | ||||||
Total liabilities and stockholders' equity | $ | 7,002,628 | $ | 6,686,568 | ||||
LIFELOC TECHNOLOGIES, INC. | ||||||||
| Three Months Ended September 30, | ||||||||
REVENUES: | 2026 | 2025 | ||||||
Product sales | $ | 2,512,530 | $ | 2,241,331 | ||||
Royalties | 9,344 | 16,117 | ||||||
Total | 2,521,874 | 2,257,448 | ||||||
COST OF SALES | 1,431,792 | 1,350,755 | ||||||
GROSS PROFIT | 1,090,082 | 906,693 | ||||||
OPERATING EXPENSES: | ||||||||
Research, development, and sustaining engineering | 505,982 | 458,747 | ||||||
Sales and marketing | 314,948 | 341,567 | ||||||
General and administrative | 319,223 | 340,705 | ||||||
Total | 1,140,153 | 1,141,019 | ||||||
OPERATING (LOSS) | (50,071 | ) | (234,326 | ) | ||||
OTHER INCOME (EXPENSE): | ||||||||
Interest income | 8,734 | 7,840 | ||||||
Interest expense | (43,594 | ) | (36,953 | ) | ||||
Total | (34,860 | ) | (29,113 | ) | ||||
NET (LOSS) BEFORE PROVISION FOR TAXES | (84,931 | ) | (263,439 | ) | ||||
BENEFIT FROM FEDERAL AND STATE INCOME TAXES | - | - | ||||||
NET (LOSS) | $ | (84,931 | ) | $ | (263,439 | ) | ||
NET (LOSS) PER SHARE, BASIC | $ | (0.03 | ) | $ | (0.10 | ) | ||
NET (LOSS) PER SHARE, DILUTED | $ | (0.03 | ) | $ | (0.10 | ) | ||
WEIGHTED AVERAGE SHARES, BASIC | 2,752,616 | 2,752,616 | ||||||
WEIGHTED AVERAGE SHARES, DILUTED | 2,752,616 | 2,752,616 | ||||||
LIFELOC TECHNOLOGIES, INC. | ||||||||
| Nine Months Ended September 30, | ||||||||
REVENUES: | 2026 | 2025 | ||||||
Product sales | $ | 7,236,986 | $ | 6,695,638 | ||||
Royalties | 23,657 | 41,588 | ||||||
Rental income | - | 16,632 | ||||||
Total | 7,260,643 | 6,753,858 | ||||||
COST OF SALES | 4,090,961 | 4,014,000 | ||||||
GROSS PROFIT | 3,169,682 | 2,739,858 | ||||||
OPERATING EXPENSES: | ||||||||
Research, development, and sustaining engineering | 1,480,708 | 1,551,689 | ||||||
Sales and marketing | 949,145 | 1,015,651 | ||||||
General and administrative | 1,021,478 | 1,065,657 | ||||||
Total | 3,451,331 | 3,632,997 | ||||||
OPERATING (LOSS) | (281,649 | ) | (893,139 | ) | ||||
OTHER INCOME (EXPENSE): | ||||||||
Interest income | 24,121 | 31,128 | ||||||
Interest expense | (114,446 | ) | (87,753 | ) | ||||
Total | (90,325 | ) | (56,625 | ) | ||||
NET (LOSS) BEFORE PROVISION FOR TAXES | (371,974 | ) | (949,764 | ) | ||||
BENEFIT FROM FEDERAL AND STATE INCOME TAXES | - | - | ||||||
NET (LOSS) | $ | (371,974 | ) | $ | (949,764 | ) | ||
NET (LOSS) PER SHARE, BASIC | $ | (0.14 | ) | $ | (0.35 | ) | ||
NET (LOSS) PER SHARE, DILUTED | $ | (0.14 | ) | $ | (0.35 | ) | ||
WEIGHTED AVERAGE SHARES, BASIC | 2,752,616 | 2,733,490 | ||||||
WEIGHTED AVERAGE SHARES, DILUTED | 2,752,616 | 2,733,490 | ||||||
Lifeloc Technologies, Inc. | |||||||||||||||
| 2026 | |||||||||||||||
| Common Stock Shares | Common Stock Amount | Retained Earnings (Accumulated Deficit) | Total | ||||||||||||
Beginning balance, December 31, 2025 | 2,752,616 | $ | 5,934,314 | $ | (1,830,536 | ) | $ | 4,103,778 | |||||||
Net (loss) | - | - | (152,713 | ) | (152,713 | ) | |||||||||
Ending balance, March 31, 2026 | 2,752,616 | 5,934,314 | (1,983,249 | ) | 3,951,065 | ||||||||||
Net (loss) | - | - | (134,330 | ) | (134,330 | ) | |||||||||
Ending balance, June 30, 2026 | 2,752,616 | 5,934,314 | (2,117,579 | ) | 3,816,735 | ||||||||||
Net (loss) | - | - | (84,931 | ) | (84,931 | ) | |||||||||
Ending balance, September 30, 2026 | 2,752,616 | $ | 5,934,314 | $ | (2,202,510 | ) | $ | 3,731,804 | |||||||
| 2025 | ||||||||||||||||
| Common Stock Shares | Common Stock Amount | Retained Earnings (Accumulated Deficit) | Total | |||||||||||||
Beginning balance, December 31, 2024 | 2,664,116 | $ | 5,586,014 | $ | 639,863 | $ | 6,225,877 | |||||||||
Issuance of shares from option exercise | 88,500 | 336,300 | - | 336,300 | ||||||||||||
Warrants issued with subordinated debenture | - | 12,000 | - | 12,000 | ||||||||||||
Net (loss) | - | - | (292,686 | ) | (292,686 | ) | ||||||||||
Ending balance, March 31, 2025 | 2,752,616 | 5,934,314 | 347,177 | 6,281,491 | ||||||||||||
Net (loss) | - | - | (393,639 | ) | (393,639 | ) | ||||||||||
Ending balance, June 30, 2025 | 2,752,616 | 5,934,314 | (46,462 | ) | 5,887,852 | |||||||||||
Net (loss) | - | - | (263,439 | ) | (263,439 | ) | ||||||||||
Ending balance, September 30, 2025 | 2,752,616 | $ | 5,934,314 | $ | (309,901 | ) | $ | 5,624,413 | ||||||||
LIFELOC TECHNOLOGIES, INC. | ||||||||
| Nine Months Ended September 30, | ||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | 2026 | 2025 | ||||||
Net (loss) | $ | (371,974 | ) | $ | (949,764 | ) | ||
Adjustments to reconcile net income (loss) to net cash | ||||||||
(used in) operating activities- | ||||||||
Provision for doubtful accounts, net change | - | 1,500 | ||||||
Depreciation and amortization | 213,133 | 325,095 | ||||||
Amortization of debt issuance costs | 18,153 | 11,937 | ||||||
Changes in operating assets and liabilities- | ||||||||
Accounts receivable | (13,062 | ) | (133,415 | ) | ||||
Inventories | (44,420 | ) | 134,239 | |||||
Federal and state income taxes receivable | 600 | 24,729 | ||||||
Prepaid expenses and other | (35,922 | ) | (102,583 | ) | ||||
Deposits and other | (34,740 | ) | (34,559 | ) | ||||
Accounts payable | 241,715 | 133,342 | ||||||
Customer and tenant deposits | (23,005 | ) | (25,885 | ) | ||||
Accrued expenses | 23,453 | 34,753 | ||||||
Deferred revenue | 11,451 | 2,174 | ||||||
Net cash provided from (used in) operating | ||||||||
activities | 14,618 | (578,437 | ) | |||||
CASH FLOWS (USED IN) INVESTING ACTIVITIES: | ||||||||
Purchases of sales and marketing equipment | (5,370 | ) | (39,510 | ) | ||||
Purchases of research and development equipment, software and | ||||||||
space modifications | (211,741 | ) | (310,646 | ) | ||||
Net cash (used in) investing activities | (217,111 | ) | (350,156 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Principal payments made on term loan | (42,592 | ) | (41,356 | ) | ||||
Proceeds from issuance of subordinated debenture | - | 75,000 | ||||||
Proceeds from issuance of term loan | 500,000 | - | ||||||
Principal payments made on subordinated debentures | (41,141 | ) | - | |||||
Proceeds from issuance of shares from option exercise | - | 336,300 | ||||||
Net cash provided from financing | ||||||||
activities | 416,267 | 369,944 | ||||||
NET INCREASE (DECREASE) IN CASH | 184,538 | (558,649 | ) | |||||
CASH, BEGINNING OF PERIOD | 746,001 | 1,243,746 | ||||||
CASH, END OF PERIOD | $ | 930,539 | $ | 685,097 | ||||
SUPPLEMENTAL INFORMATION: | ||||||||
Cash paid for interest | $ | 96,292 | $ | 75,816 | ||||
Income tax refund received | $ | - | $ | 24,729 | ||||
Non-cash financing and investing activities: warrants issued with | ||||||||
subordinated debenture | $ | - | $ | 12,000 | ||||
Amy Evans
Lifeloc Technologies, Inc.
http://www.lifeloc.com
(303) 431-9500
SOURCE: Lifeloc Technologies, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Lifeloc's third-quarter 2026 earnings results?
Lifeloc reported revenue of $2,521,874 and a net loss of $84,931, or $0.03 per diluted share, for the quarter ended September 30, 2026. A year earlier, revenue was $2,257,448 and net loss was $263,439, or $0.10 per diluted share.
When does Lifeloc expect to launch SpinDetect?
Lifeloc expects a limited commercial launch in Q4 2027, revised from Q1 2027. The timeline depends on anticipated incremental revenue from core products and timely access to capital for fabrication, validation, regulatory preparation and market introduction.
How will Lifeloc staff SpinDetect testing while upgrading its alcohol-testing products?
Lifeloc plans to conduct SpinDetect beta testing and validation with current staff rather than additional personnel. A portion of engineering and development resources is being redirected to core alcohol-testing products after earlier deferrals of upgrades and enhancements.